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RESUMO 
A beta talassémia é uma doença genética que se caracteriza pela redução ou ausência de 
síntese de beta globina, um dos constituintes da hemoglobina, resultando no aumento de glóbulos 
vermelhos e, consequentemente, em anemia. Uma das causas desta doença tem origem na alteração 
de um nucleótido, levando à introdução de um codão de terminação prematura (na sigla inglesa PTC 
ou codão nonsense) nos transcritos de beta globina. A presença de um PTC não permite que a 
tradução progrida normalmente, ocorrendo, na maior parte dos casos, a formação de péptidos 
truncados que são, possivelmente, não funcionais ou, até, tóxicos para a célula.  
No sentido de recuperar a homeostase, a célula desenvolveu mecanismos de controlo de 
qualidade para assegurar a fidelidade da expressão genética. Entre estes mecanismos está o 
decaimento do RNA mensageiro (mRNA) mediado por mutações nonsense (na sigla inglesa NMD – 
nonsense mediated mRNA decay) que permite identificar e degradar transcritos que contenham um 
PTC, reduzindo a sua abundância. Deste modo, a eliminação destes transcritos anómalos evita a 
formação e acumulação de proteínas truncadas que, caso contrário, danificariam a célula. Assim, o 
NMD tem, na maioria dos casos, um papel protetor contra erros genéticos. A degradação do 
transcrito que contém o PTC inicia-se logo após a exportação da ribonucleoproteína mensageira (na 
sigla inglesa mRNP) para o citoplasma. Durante a ronda pioneira de tradução, se o transcrito não 
possuir um PTC, o ribossoma remove da mRNP todos os complexos de junção exão-exão (na sigla 
inglesa EJC) até chegar ao codão de terminação. Os EJC são complexos multiproteicos, depositados 
20 a 24 nucleótidos (nt) de distância a montante das junções exão-exão (local de excisão dos intrões) 
durante o splicing. Se, por ventura, o transcrito possuir um PTC e este se localizar a, pelo menos, 50 a 
55 nt de distância a montante da última junção exão-exão, a tradução é terminada prematuramente 
e pelo menos um EJC fica associado ao mRNA. Nestas condições, o EJC facilita o recrutamento e a 
interacção dos factores do NMD com o complexo de terminação da tradução, activando o NMD. Este 
é o caso mais comum, no qual o transcrito é degradado, reduzindo os seus níveis drasticamente 
(entre 0 a 20% dos níveis normais). Como exemplo para esta situação temos o caso do transcrito de 
beta globina com uma mutação nonsense no codão 39. Contudo, esta regra posicional dos EJC não é 
tão linear como aparenta, dado que existem transcritos que, mesmo estando nas condições previstas 
pelo modelo, conseguem resistir à acção do NMD, como é o caso de mRNAs que contenham PTCs 
próximos do codão de iniciação. Como exemplo de um mRNA que escapa à degradação pelo NMD, 
temos o transcrito de beta globina que possui uma mutação nonsense no codão 15, sendo que os 
seus níveis de expressão são semelhantes aos do gene da beta globina normal. De facto, verificou-se 
que existem outras características do mRNA, para além dos EJC, que influenciam a activação do 
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NMD, tais como distância física entre um PTC e a proteína citoplasmática de ligação à cauda poli-A do 
mRNA (na sigla inglesa PABPC1). Para além disso, o tamanho da região não traduzida a 3’ (na sigla 
inglesa 3’UTR) é outro dos fatores que influencia a ativação do NMD. Apesar de, na maioria dos 
casos, o NMD assumir um papel protector, este pode também agravar o fenótipo da doença pelo 
facto de eliminar mRNAs que originam proteínas parcialmente funcionais ou com actividade residual. 
O processo de terminação da tradução ocorre quando o codão stop é reconhecido por 
proteínas que formam o complexo de terminação, promovendo a libertação da cadeia polipeptídica 
formada até então. Em certos casos, ao invés de ser reconhecido pelo complexo de terminação, o 
codão stop é identificado por um aminoacil tRNA, complementar a duas das três bases (na 
terminologia inglesa near cognate aminoacyl tRNA). Ocorre, assim, a recodificação do codão de 
terminação prematura, permitindo que a elongação prossiga em fase, até que o ribossoma atinja um 
codão stop normal, possibilitando a formação da proteína completa e potencialmente funcional. Este 
processo de readthrough de um PTC ocorre espontaneamente na célula, embora não seja frequente 
(cerca de 1%). No entanto, certas moléculas de baixo peso molecular demonstram elevar a 
frequência destes acontecimentos, uma vez que favorecem a competição entre os near cognate 
aminoacyl tRNAs e o complexo de terminação. Desta forma, nas últimas décadas tem sido 
desenvolvida uma terapia, designada como terapia de supressão, que utiliza estes compostos com 
vista a aliviar os sintomas de diversas doenças causadas por mutações nonsense, devido ao aumento 
da quantidade de proteína funcional disponível. Os compostos mais estudados e utilizados na terapia 
de supressão são os aminoglicosídeos, um grupo de antibióticos cujo potencial de supressão provém 
da sua capacidade de reduzir a fidelidade na incorporação dos aminoácidos (na terminologia inglesa 
misincorporation), promovendo a introdução de near cognate aminoacyl tRNAs. À parte dos 
aminoglicosídeos, existe um composto, o PTC124, que tem vindo a ser alvo de grande interesse 
devido ao facto de não apresentar actividade antibacteriana nem toxicidade, assumindo um papel 
promissor no desenvolvimento da terapia de supressão. 
Este trabalho teve como objectivo investigar se os dois compostos a testar, o aminoglicosídeo 
G418 (geneticina) e o não-aminoglicosídeo PTC124 (atalureno), possuem a capacidade de aumentar 
os níveis de beta globina normal para, possivelmente, atenuar as manifestações da beta talassémia 
devido a mutações nonsense. Para tal, foi delineada uma estratégia experimental, que consiste em 
transfectar células HeLa com plasmídeos que contêm o gene da beta globina humana normal (BN) ou 
o equivalente com uma mutação nonsense no codão 39 (B39), expondo-as aos dois compostos. No 
final, foram  analisadas as diferenças nos níveis de mRNA, consoante as concentrações utlizadas. Os 
nossos resultados mostraram que o G418 produz diferenças subtis entre as amostras tratadas e não 
tratadas, não sendo claro se o composto é capaz de aumentar os níveis de mRNA da beta globina, no 
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modelo experimental usado. Os resultados relativamente ao composto PTC124 foram, de certa 
forma, inconsistentes, uma vez que o aumento dos níveis de mRNA não foi idêntico ao longo das 
experiências, embora seja bastante normal aquando de uma fase de testes. Ainda assim, o PTC124 
induziu o aumentou de 4 vezes os níveis de mRNA do transcrito B39 na concentração de 100µM, 
quando comparamos com o B39 sem tratamento, o que pode indicar um possível efeito da droga, 
embora as diferenças observadas não sejam estatisticamente significativas.  
De modo a obter resultados mais esclarecedores, é aconselhável testar diferentes 
concentrações para ambas as drogas. Devido ao facto de não ter sido possível testar o efeito das 
drogas relativamente à sua expressão proteica, no futuro seria de grande interesse avaliar o efeito 
destes dois compostos a este nível. Para além disso, a utilização de outro modelo celular, como as 
células MEL (murine erythroleukemia), seria de grande interesse, devido ao facto de se tratar de 
células eritróides. Uma vez que a terapia de supressão é uma abordagem na qual é extremamente 
difícil alcançar resultados consistentes, reprodutíveis e satisfatórios, futuramente é recomendável 
acoplar esta terapia com outras metodologias, por exemplo, a inibição do NMD.  
Apesar da investigação no ramo da terapia de supressão ser bastante complexa e exigente, é 
de recordar que este tratamento não se foca nos sintomas, mas sim na origem molecular de muitas 
doenças genéticas. 
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ABSTRACT 
Nonsense mutations are alterations that introduce, prematurely, in the coding region of the 
messenger RNA (mRNA), a translational termination codon. Nonsense mutations or premature 
termination codons (PTCs) can arise from various types of mutations in germ or somatic cells. PTCs 
promote premature translational termination and, in most cases, the induction of nonsense-
mediated mRNA decay (NMD). NMD is a quality control pathway that recognizes and rapidly 
degrades mRNAs that contain PTCs, preventing the synthesis of C-terminally truncated proteins, 
possibly toxic for the cell. In recent years, a therapeutic approach called suppression therapy is being 
developed using low molecular weight compounds to induce the translation machinery to recode a 
PTC into a sense codon. Beta thalassemia is one of the most common genetic diseases worldwide, 
being characterized by reduced or absent beta globin chain synthesis, resulting in diminished 
hemoglobin in red blood cells, increased red blood cells production and anemia. Some studies have 
shown that aminoglycosides and non-aminoglycosides can suppress PTCs in cystic fibrosis and 
Duchenne’s muscular dystrophy, but it remains unclear whether beta thalassemia would also be 
responsive to a similar drug treatment. Preliminary results obtained in our lab have shown that the 
aminoglycoside G418 (geneticin) can suppress a nonsense mutation at codon 39 of the human beta 
globin mRNA, although at low levels in cultured erythroid cells. To investigate if suppression therapy 
can restore enough beta globin protein to possibly correct the disease manifestations of beta 
thalassemia, HeLa cells were transfected with plasmids containing the human beta globin wild type 
gene (BN) or the counterpart carrying a nonsense mutation at codon 39 (B39). HeLa cells were then 
treated with G418 or PTC124 (ataluren) to ascertain if these compounds are able to induce efficient 
levels of suppression, in a dose-dependent manner.  Our results showed that G418 produces slight 
differences between the treated and untreated samples, and so it is not clear if the compound is 
capable of restoring beta globin mRNA levels. Results from PTC124 treatment were somehow 
inconsistent because the increase of the mRNA levels was not identical throughout the experiments, 
although it is quite normal considering a testing phase. On the other hand, PTC124 increased nearly 
4-fold the mRNA levels of the B39 transcript when comparing with the B39 without treatment, which 
may indicate a possible effect of the drug, although the observed differences are not statistically 
significant. To obtain more clarifying results we suggest testing more drug concentration ranges. Due 
to the fact that we were unable to test the effect of the drug on the protein level, in the future it 
would be of great interest to evaluate the effect of these two compounds on protein expression 
levels. Additionally, since suppression therapy is an extremely difficult approach to achieve efficient 
results, future methodologies should combine this therapy with others, for example, NMD inhibition.  
xi 
 
KEYWORDS 
Messenger RNA translation, nonsense mutation, suppression therapy, G418, PTC124. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
ABBREVIATIONS 
 
A-site   aminoacyl-site  
B15  human beta globin transcript with a PTC at codon 15   
B39  human beta globin transcript with a PTC at codon 39  
BN   normal/wild type human beta globin transcript 
CBC    cap binding complex  
CBP   cap binding protein  
cDNA   complementary deoxyribonucleic acid   
C-terminal  carboxyl-terminal  
DECID  decay inducing complex  
DMEM   Dulbecco's modified Eagle medium  
DNA   deoxyribonucleic acid   
eEF   eukaryotic translation elongation factor  
eIF   eukaryotic initiation factor   
EJC  exon junction complex  
eRF  eukaryotic translation release factor   
G418 geneticin 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GTP   guanosine triphosphate   
h    hour(s)   
HeLa   human cervical cancer cell line  
Met   metionin   
Met-tRNAi   methionine-loaded initiator tRNA  
min  minute(s)   
mRNA    messenger ribonucleic acid   
mRNP   messenger ribonucleoprotein particle  
NMD   nonsense-mediated mRNA decay   
NP40  nonidet-P40   
nt   nucleotide   
ORF  open reading frame  
PABP  poly(A)-binding protein  
PABPC1  cytoplasmic poly(A)-binding protein 1  
PBS   phosphate buffered saline  
PCR  polymerase chain reaction   
Poly(A)   poly-adenilate   
P-site   peptidyl-site  
PTC  premature translation termination codon  
PTC124 ataluren 
Puro  puromycin   
RNA   ribonucleic acid   
RT  reverse transcription  
RT-qPCR   reverse transcription quantitative polymerase chain reaction   
SDS sodium dodecyl sulphate 
SMG   suppressor of morphological defects on genitalia  
SURF  SMG1-UPF1-eRFs complex  
tRNA   transfer ribonucleic acid   
UPF   up-frameshift protein  
UTR  untranslated region  
WT   wild type  
α-tub  α-tubulin 
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1. INTRODUCTION 
1.1. Beta thalassemia 
Beta thalassemia is one of the most common autosomal recessive disorders worldwide1, being 
the total annual incidence of symptomatic individuals estimated at 1 in 100,000 throughout the 
world and 1 in 10,000 people in the European Union2. This disease is more prevalent in 
Mediterranean countries, the middle east, central Asia, India, southern China, north coast of Africa 
and in south America. The highest carrier frequency is reported in Cyprus (14%), Sardinia (10.3%), 
and southeast Asia (3-5%)3. The high frequency of beta thalassemia in these regions is most likely 
related to the selective pressure from Plasmodium falciparum, which causes malaria3. 
Beta thalassemia is  a genetic disease caused by mutations in the beta globin (HBB) gene4.  The 
HBB gene, which spans 1.6 Kb, contains three exons and two introns, is located in the short arm of 
chromosome 11 in a cluster also containing the delta globin gene, the embryonic epsilon gene, the 
fetal A-gamma and G-gamma genes, and a pseudogene1. More than 200 mutations have been 
identiﬁed to cause beta thalassemia. The majority are nonsense mutations, defined as an alteration 
in a single nucleotide base, which results in an in-frame premature termination codon (PTC) in the 
coding region5. The introduction of a PTC originates a smaller truncated protein, which can lead to a 
complete loss of protein function and a reduction in mRNA levels due to nonsense-mediated mRNA 
decay (NMD)5. PTCs can occur for numerous reasons, namely point or frameshift mutations, 
programmed DNA rearrangements and errors in RNA splicing6. Rarely beta thalassemias result from 
gross gene deletion1. As a consequence, this disease is characterized by reduced (beta+) or absent 
(beta0) beta globin chain synthesis, resulting in diminished hemoglobin (Hb) in red blood cells (RBC), 
increased RBC production and anemia2.  
This disease can exhibit variable phenotypes extending from severe anemia to clinically 
asymptomatic individuals. There are three forms of beta thalassemia: thalassemia major, thalassemia 
intermedia and thalassemia minor. Individuals with thalassemia major usually present, within the 
first two years of life, severe anemia requiring regular RBC transfusions. Thalassemia intermedia 
reveals its symptoms later in life with moderate anemia and do not require regular transfusions. 
Thalassemia minor is clinically asymptomatic but some patients may have moderate anemia2. The 
clinical severity of beta thalassemia is related to the extent of imbalance between the alpha and non-
alpha globin chains1. 
As far as the control of the disease is concerned, RBC transfusions are required to increase the 
oxygen-carrying capacity of the blood through raising the hemoglobin concentration of patients with 
acute or chronic anemia7. Thus, in patients with thalassemia major, regular transfusions correct the 
anemia, suppress erythropoiesis, and inhibit increased gastrointestinal absorption of iron. The 
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transfusion procedure is designed to obtain an Hb concentration of 95–100 g/L, given every 2–3 
weeks1. Splenectomy and folic acid supplementation is a characteristic treatment for patients with 
thalassemia intermedia, being the RBC transfusions sporadic. Treatment by means of transfusion has 
many disadvantages being the most common iron overload. This problem can be surpassed with 
chelation therapy using desferrioxamine B or, less often, deferiprone and deferasirox. Chelation 
therapy using these agents has many side effects due to their toxicity at diverse levels (ocular and 
auditory toxicity, growth retardation and several others), requiring close monitoring1. 
Owing to the fact that beta thalassemia is a disease with high prevalence, its symptoms can be 
very severe and the associated therapy is complex and entails many collateral issues, it is a need to 
develop a treatment being the suppression therapy an alternative. 
1.2. Nonsense-mediated mRNA decay 
Cells produce a large number of damaged mRNAs, which harbour premature termination 
codons (PTCs) that are eliminated by nonsense-mediated mRNA decay (NMD). NMD is a post-
transcriptional quality control mechanism that exists in all eukaryotes8. It acts by identifying and 
inducing the degradation of newly synthesized transcripts that harbour PTCs, preventing, in this 
manner, the production of truncated proteins that may be harmful for the cell9. Besides having its 
role on the degradation of aberrant transcripts, NMD also participate in the downregulation of many 
physiological mRNAs acting as a controller of gene expression in response to cellular needs8–10. The 
biological significance of  NMD is evidenced by the fact that, as mentioned before, approximately 
30% of all inherited genetic disorders are due to PTCs and NMD is capable of influencing the severity 
of the clinical phenotype11. In most cases, NMD has a beneficial effect by eliminating transcripts 
harbouring PTCs that would give rise to truncated proteins either with a complete loss of function or 
with a dominant-negative function leading to toxicity. Besides, NMD can also aggravate the disease 
phenotype by eliminating mRNAs that would originate partially functional proteins12.  
It is important to underline that NMD strictly depends on reading frame recognition and 
consequently on translation9. The degradation of mRNAs that contain PTCs is initiated with the 
detection of the NMD target and it takes place during the pioneer round of translation, where the 
newly synthesized messenger ribonucleoprotein complexes (mRNP) are exported to the cytoplasm 
and then remodeled13,14. At this stage the 5’ end of the transcript is bound to the cap-binding protein 
heterodimer CBP80-CBP20, which constitutes the cap-binding complex (CBC) (Figure 1a). Exon-
junction complexes (EJCs) are also bound to the mRNP, deposited 20-24 nucleotides (nts) upstream 
of exon-exon junctions15, being a hallmark from splicing8. At the 3’ end, poly(A)-binding protein 
nuclear 1 (PABPN1) and poly(A)-binding protein cytoplasmic 1 (PABPC1) bind to the poly(A) tail. 
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Remodeling of mRNP includes replacement of CBC for eukaryotic translation initiation factor 4E 
(eIF4E); removal of EJCs and replacement of PABPN1 for PABPC113. During remodelling the ribosome 
displaces from the open reading frame (ORF) any EJC deposited in the mRNA, until it reaches a stop 
codon. If the transcript possesses a PTC localized at more than 50-55 nts upstream of the last exon-
exon junction16, the ribosome is incapable to physically remove the EJC. In contrast, if the PTC is 
located at less than 50-55 nucleotides upstream of the last exon-exon junction of a transcript, all EJCs 
are removed and the NMD is not activated. However, the “50-55nt rule” is not the only determinant 
on the NMD activation. For example, the beta globin transcripts possessing a PTC near the AUG fail 
to trigger NMD, despite the existence of downstream EJCs17. In fact, it has been suggested that the 
decision of whether NMD is triggered or not relies on the competition between UPF1 and PABPC1 for 
binding to eRF3 on the terminating ribosome. If PABPC1 is in close proximity to a stop codon, it 
interacts with the termination complex, stimulating proper translation termination, and represses 
NMD. On the other hand, if the distance between the terminating ribosome and the poly(A) tail is 
large, the interaction of PABPC1 with the termination complex is reduced and UPF1 interacts with 
eRF3 triggering NMD18. Thus, the presence of an EJC downstream of a stop codon is characteristic of 
PTC-containing mRNAs and not of most normal endogenous mRNAs, being this situation considered 
aberrant and consequently NMD is activated13,15.  
In human cells, the surveillance complex comprises the factors up-frameshift 1 (UPF1), UPF2 
and UPF3 and the suppressor with morphogenetic effects on genitalia 1 (SMG1), SMG5, SMG6 and 
SMG7. UPF1 is a highly conserved ATP-dependent RNA helicase and is the central NMD factor. UPF1 
associates with the terminating ribosome through interaction with the eukaryotic release factor 1 
(eRF1) - eRF3 heterodimer, forming a complex with SMG1, called the SURF complex (SMG1-UPF1-
eRFs complex)19 (Figure 1a). UPF1 also binds to UPF2 and UPF3 forming the decay-inducing complex 
(DECID), which promotes UPF1 phosphorylation by the protein kinase SMG1 (Figure 1b and c). 
Hyperphosphorylation of UPF1 is a prerequisite for degradation of PTC-bearing mRNAs because it 
contributes to the recruitment of the additional SMG factors13 (Figure 1d). Depending on the 
recruited SMG factor two different strategies of degradation can be performed. The recruitment of 
SMG6 causes an endonucleolytic cleavage between the PTC and the EJC, resulting two fragments 
that will be degraded by exonucleases. On the other hand, when SMG5-SMG7 or SMG5-PNRC2 
(proline-rich nuclear receptor 2) are involved, they further recruit decapping and/or deadenylating 
enzymes, promoting the exonucleolytic degradation of the mRNA8,9,13,15 (Figure 1e).  
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a) SURF formation 
 
 
 
 
 
 
 
 
 
 
 
b) UPF1-SMG1 joins EJC leading to DECID formation 
 
 
 
 
 
c) SMG1-mediated UPF1 phosphorylation 
 
 
 
 
 
 
 
d) Translational repression and mRNA decay 
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e) Two different pathways of degradation: 
 
Endonucleolytic cleavage by SMG6 followed by exonucleolytic degradation 
 
 
 
  
 
 
 
 
 
 
Decapping and/or deadenylation followed by exonucleolytic degradation 
 
 
 
 
 
 
 
 
 
 
Figure 1: Nonsense-mediated mRNA decay (Adapted from Popp & Maquat, 2014)
13
. Immediately after 
nuclear export, mRNP is subject to pioneer round(s) of translation. a) If a premature termination codon 
(PTC) resides ≥ 50-55 nucleotides (nts) upstream of an exon-exon junction that is bound by an EJC, then CBC 
escorts UPF1−SMG1 to the eRF3 constituent of the eRF1−eRF3 heterodimer in the context of the 
terminating ribosome, forming the SURF complex. b) CBC also escorts UPF1−SMG1 to the EJC, to which 
UPF2 is bound via UPF3 or UPF3X to form the DECID complex. c) In this configuration, SMG1 phosphorylates 
various serines and threonines near the N- and C-termini of UPF1, producing hyperphosphorylated UPF1. d) 
UPF1 activation via phosphorylation has several functions namely the induction of translational repression 
and the recruitment of several enzymes that, depending on which are involved, will culminate in two 
different pathways of degradation (e).  Upper panel: Recruitment of SMG6 will produce one or more 
endonucleolytic cleavages between the PTC and EJC, leaving bare extremities, exposed to the action of 
exonucleases. Bottom panel: Recruitment of SMG5−SMG7 or SMG5−PNRC2, which further recruit 
decapping and/or deadenylating enzymes facilitating exonucleolytic degradation of the mRNA. 
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1.3. Translation 
Translation of mRNA into protein represents the final step in the gene expression pathway, 
which mediates the formation of the proteome from genomic information20. The translation process 
can be divided into four stages - initiation, elongation, termination and ribosome recycling - each of 
which requires a particular set of conditions and factors21.  
Translation initiation requires the function of several eukaryotic translation initiation factors 
(eIFs) as well as the assembly of elongation-competent 80S ribosomes at the initiation codon 
(generally AUG). Commonly, the start codon is identified by a scanning mechanism, where the 43S 
pre-initiation complex binds to the mRNA at the 5’ untranslated region (5’UTR) scanning for an AUG 
codon. The 43S pre-initiation complex comprises the small (40S) ribosomal subunit, the eIFs 3, 1, 1A, 
5 and a ternary complex, which consists of the methionine-loaded initiator tRNA (Met-tRNAi
Met) and 
eIF2 coupled to GTP20,22,23. Binding of the 43S pre-initiation complex to the mRNA requires the 
cooperative action of eIF4G and eIF4E subunits of the cap-binding complex (CBC). In addition, the 
CBC contains an RNA helicase - eIF4A - which unwinds the 5’UTR of the mRNA allowing ribosomal 
attachment. After a stable binding of the 43S pre-initiation complex to the AUG codon, the large 
(60S) ribosomal subunit joins, resulting in the formation of the 80S initiation complex which is 
competent to catalyze the formation of the first peptide bond and start elongation24,25. 
Translation elongation represents the ordered addition of amino acids to the growing 
polypeptide chain by ribosomes. Ribosomes have three tRNA-binding sites: the A-site, which accepts 
the incoming aminoacyl-tRNA, the P- (peptidyl) site, which holds the tRNA with the nascent peptide 
chain and the E- (exit) site that holds the deacylated tRNA before it leaves the ribosome26. Various 
aminoacyl-tRNAs successively enter the A site as ternary complexes with the translation elongation 
factor eEF1A and GTP until a cognate tRNA (carrying an anticodon with a correct match for the 
codon) is selected. This process is monitored at two distinct steps separated by the irreversible step 
of GTP hydrolysis by eEF1A, thus ensuring that aminoacyltRNA selection is achieved with a high level 
of accuracy5,27.  
The process of adding amino acids is repeated numerous times, until a stop codon is reached. 
Two translation termination factors are required to mediate eukaryotic translation termination. eRF1 
directly recognizes any of the three stop codons (UAA, UAG, and UGA). Notably, codon recognition 
during termination is the only step in translation where a protein factor—rather than a nucleic acid 
adaptor (the tRNA)—serves as the adaptor that decodes a codon. The second termination factor, 
eRF3, is a GTPase that binds eRF1 and assists in the termination process28,29. When a stop codon 
enters the ribosomal A site to form the pre-termination complex, the process of sampling to identify 
the appropriate binding partner occurs again. This includes both aminoacyl-tRNAs (in a ternary 
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complex with eEF1A and GTP) and the release factor eRF1 (in a ternary complex with eRF3 and GTP). 
Upon initial stop codon recognition by eRF1, GTP hydrolysis by eRF3 induces conformational changes 
in eRF1 that finalize stop codon recognition. This allows eRF1 to stimulate hydrolysis of the ester 
bond of the peptidyl-tRNA, thus facilitating the release of the completed polypeptide chain5,28. 
1.4. Suppression therapy 
Nonsense mutations are associated with one third of all genetic disorders, comprising many 
types of cancer4. Several of these diseases do not have an efficient treatment and hence the 
relevance to discover a cure. PTC suppression was first described in 1996 as a potential therapy for 
diseases caused by nonsense mutations in the CFTR gene (mutations in which result in the common 
genetic disease Cystic Fibrosis). That study demonstrated that the aminoglycoside geneticin (G418) 
suppresses nonsense mutations in the CFTR gene and restores significant levels of both CFTR protein 
and function in cultured cells30.  
The introduction of a PTC in the ORF will terminate mRNA translation prior to the completion 
of a full length polypeptide, leading to the formation of a truncated protein that can be non-
functional or unstable. mRNAs containing PTCs are, most of the time, degraded by surveillance 
mechanisms namely NMD (previously addressed), being the available functional protein scarce or 
inexistent, originating the symptoms of the disease. In the last decades a therapeutic approach that 
utilizes low molecular weight compounds has been developed, which induce the translation 
machinery to recode a PTC into a sense codon31. By these means, the translation elongation will 
continue in the correct reading frame until it reaches the normal stop codon, allowing the formation 
of the full-length polypeptide.  
During translation elongation, the recognition of a sense codon differs from the recognition of 
a stop codon since those sense codons are identified by aminoacyl tRNAs but stop codons are 
recognized by proteins called eukaryotic release factors (eRF). Thus, when a stop codon enters the A 
site of a ribosome the sampling of aminoacyl tRNAs is initiated as it does on the sense codons but 
since there are no aminoacyl tRNAs that are completely matching, an eRF binds inducing the 
releasing of the polypeptide chain (Figure 2a and b). There are some aminoacyl tRNAs, near-cognate 
aminoacyl tRNAs, that are complementary to two of the three nucleotides of a stop codon and can 
compete with the release factors for the A site binding32. In the presence of the compounds that 
promote the suppression of PTCs the capacity of the near-cognate aminoacyl tRNAs to bind the A site 
is enhanced5,32,33. The process that recodes a stop codon into a sense codon is referred to as a 
“readthrough” event. The amino acid inserted during the readthrough event may not be the one 
normally encoded, however, as long as the substituted amino acid does not carry out an essential 
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function (for example, as a critical active site residue), the resulting protein may have normal or, at 
least, partial activity5 (Figure 2c). Increasing the frequency that PTCs are recoded into sense codons, 
enough full-length functional protein can be restored and consequently provide a therapeutic effect 
to patients that carry PTCs. The basal level of termination suppression at naturally occurring stop 
codons occurs at a frequency of <0.1%34. In contrast, the basal level of termination suppression at 
PTCs occurs at higher frequencies (<1%)35.  
PABP plays an important role in translation termination. Due to the fact that it is bound to the 
poly(A) tail, PABP is normally close to the termination complex at normal stop codons, allowing it to 
interact with eRF3 during translation termination and stimulate polypeptide chain release36. In 
contrast, termination at a PTC usually does not occur in proximity to the poly(A) tail, which limits the 
interaction between eRF3 and PABP and leads to prolonged ribossomal pausing at PTCs37. This has 
important implications for nonsense suppression, because it increases the extent of aminoacyl-tRNA 
sampling and makes PTCs more susceptible to readthrough5.  
Focusing on the compounds that increase the frequency that PTCs are recoded into sense codons, 
aminoglycosides are the most studied. Aminoglycosides are a class of antibiotics consisting of a 2-
deoxystreptamine ring linked to multiple amino sugars. This group of antibiotics acts by binding to 
the decoding center of the bacterial ribosome. The decoding center carries out a proofreading 
function that monitors codon–anticodon interactions to ensure that only cognate aminoacyl-tRNAs 
are correctly accommodated into the peptidyltransferase center where peptide bond formation can 
occur. This characteristic of aminoglycosides is the key factor in suppression therapy because it 
allows the reduction of ribosome’s proofreading activity, enhancing the misincorporation of near-
cognate aminoacyl tRNAs into the ribosomal A site5. Even though aminoglycosides lead to an 
extensive translational misincorporation in bacteria, the same is not verified in eukaryotes.  Various 
aminoglycosides, including gentamicin, amikacin, paromomycin, G418 (geneticin), lividomycin, 
tobramycin, and streptomycin have been shown to suppress disease-causing PTCs in mammalian 
cells and partially restore protein function38,39. Although these results are promising, there are 
several obstacles that must be overcome before aminoglycosides can be used long-term in the 
suppression of nonsense mutations. On the one hand, the efficiency of suppressing PTCs is greatly 
influenced by the sequence of the stop codon and the context of the surrounding mRNA sequence. 
On the other hand, the use of aminoglycosides long-term is limited due to toxic side effects, which 
include nephrotoxicity and ototoxicity. The toxicity associated with aminoglycosides does not appear 
to be attributable to their ability to suppress PTCs but due to their association with off-target sites 
such as lysosomal membranes. Apart from aminoglycosides, one of the compounds that have shown 
good results in PTC readthrough and protein function restore is PTC124, also known as Ataluren. This 
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compound is an oxadiazole discovered by PTC Therapeutics® that suppresses termination at PTCs in 
mammalian cells without affecting translation termination at natural stop codons40. Preclinical 
studies showed that PTC124 is safe, has minimal off-target side effects, has no antibacterial activity, 
and is orally bioavailable5. 
 
Figure 2: The effect of readthrough compounds on protein translation (Adapted from Carriço et al, 2012)
28
. (a) 
During normal translation, a tRNA carrying the appropriate amino acid enters the A site of the rRNA, upon 
recognition of the mRNA codon by the tRNA anticodon. The peptidyl tRNA, with the nascent polypeptide, is 
located in the P site. The amino acid in the A site binds to the nascent polypeptide, and the ribosome moves 
along the mRNA three nucleotides, with transfer of the tRNA from the A site to the P site. (b) In the presence of 
a PTC, there is no tRNA matching the stop codon. Instead, the release factors eRF1 and eRF3 bind and 
terminate translation by releasing the polypeptide, which is a truncated protein. (c) When aminoglycosides or 
PTC124 (readthrough compounds – RTC) bind to the rRNA there is no premature termination of translation, 
despite the presence of a PTC. An alteration of rRNA conformation is induced upon binding of the small 
molecule, reducing the accuracy of the codon–anticodon interaction. This enables incorporation of an 
aminoacylated tRNA, moving translation towards the canonical stop codon and originating a full-length protein. 
The proteins produced may be functional, or non-functional, depending on whether the introduced amino acid 
affects conformation and/or binding to other proteins. 
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2. AIMS 
In recent years, a new therapeutic approach called suppression therapy has been developed 
that utilizes low molecular weight compounds to induce the translation machinery to recode a PTC 
into a sense codon31,41. Suppression of translation termination at a PTC allows translation elongation 
to continue in the correct reading frame so that synthesis of a full-length polypeptide can be 
completed and protein function can be restored31. The goal of suppression therapy is to enhance the 
ability of near-cognate aminoacyl tRNAs to compete with the release factor complex for binding PTCs 
in the ribosomal A site in a specific way for suppression termination at PTCs and not at natural stop 
codons32.  
Although there have been several studies showing that aminoglycosides and non-
aminoglycosides can suppress PTCs in disorders such as cystic fibrosis and Duchenne muscular 
dystrophy, it remains unclear whether different nonsense mutations responsible for beta 
thalassemia would be equally responsive to aminoglycoside or other drugs treatment. In this project 
we aim to test this hypothesis. Our preliminary results show that the aminoglycoside G418 can 
suppress a nonsense mutation at codon 39 of the beta globin mRNA, although at low levels in 
cultured erythroid cells. To further support the proof of principle that the suppression therapy can 
restore enough beta globin protein to correct the disease manifestations of beta thalassemia, we 
proposed to address: 
(i) How the beta thalassemic nonsense mutation at codon 39 will respond to nonsense 
suppression therapy with different compounds; 
(ii) Which compounds (aminoglycoside G418 and non-aminoglycoside PTC124) will have efficient 
levels of suppression, in a dose-dependent manner. 
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3. MATERIALS AND METHODS 
3.1. Plasmid construction 
The wild-type (wt) HBB gene (BN), and the two beta globin variants (with mutation at codon 15 
and 39, respectively B15 and B39) were already available in the laboratory, cloned into the pTRE2pur 
vector, as previously described in Inácio et al, 200417. The mutation at codon (CD) 15 comprises the 
alteration from TGG to TGA and the mutation at CD 39 from CAG to TAG. In order to more easily 
detect beta globin protein, c-myc tag was cloned by using an annealing reaction, where two 
oligonucleotides (Table 1), one forward #1 and another reverse #2, were designed to contain the 
sequence of the c-myc tag and the BstXI restriction sites in the extremities. (The annealing was 
performed following the temperature programme: 5 min at 95°C, 10 min at 85°C, 10 min at 75°C and 
10 min at 65°C). After annealing, this fragment was then ligated to the pTRE2pur vector, previously 
digested with the same enzyme. With this approach, only the B39_c-myc variant was obtained. The 
other two variants (BN and B15) were created through another strategy, by using two restriction 
enzymes: NotI and BsrGI, which digest, respectively, on the plasmid and on the HBB gene, as 
illustrated in figure 4 (Results section). The B39_c-myc variant was digested with these two 
restriction enzymes, resulting two fragments: one (smaller) containing the nonsense mutation, and 
another one (larger), comprising the plasmid with the c-myc tag (Appendix figure 2). In parallel, the 
BN and B15 variants were digested with the same two enzymes and the small fragment, containing 
the nonsense mutation (in the case of B15), was ligated to the large fragment, containing the c-myc 
tag, from the B39_c-myc digestion. 
 
3.2. Cell culture and plasmid transfection 
HeLa cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) 
fetal bovine serum (DMEM 1X + GlutaMAXTM-I; Gibco® by Life Technologies™, USA), incubated at 
37°C in an atmosphere containing 5% CO2. HeLa cells were plated in 35-mm plates and transfected 
with 3 µg of plasmid DNA of each variant (BN, B15 and B39). Transfection of cells was performed 
using 1mg/mL Lipofectamine® 2000 Transfection Reagent (Invitrogen® by Life Technologies™, USA) 
and Reduced Serum Medium (Opti-MEM® I (1X); Gibco® by Life Technologies™, USA), following the 
manufacturer’s instructions. In parallel, non-transfected cells were plated at the same conditions and 
used as a control. 
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3.3. Drug treatment and cell lysis 
Twenty-four hours post-transfection, cells were either treated or untreated with G418 (Sigma-
Aldrich®, USA) or with PTC124 (Selleckchem, USA). The culture medium was removed and new 
medium supplemented with 0 µg/mL, 200 µg/mL, 300 µg/mL or 500 µg/mL of G418 or 0 µM, 50 µM, 
100 µM or 150 µM of PTC124 was added. Cells were harvested 24h post treatment with the above 
mentioned drugs by rinsing with 1mL of Phosphate Bufferd Saline (PBS) and lysed through 
solubilisation and scrapping in 100 µL of Nonidet P40 1% (NP40) (Roche, Germany). Lysates were 
then stored at -80°C until they were used. Once defrosted, lysates were centrifuged for 2 minutes at 
full speed and then 40 µL of the supernatant was collected for further RNA extraction, being the 
remaining 60 µL used for protein detection by Western blot (WB). 
3.4. RNA extraction 
Total RNA was extracted from cultured HeLa cells using the RNA extraction kit NucleoSpin® 
RNA II (Macherey-Nagel, Germany) according to the manufacturer’s instructions.  
 
3.5. Reverse transcription-coupled quantitative PCR (Real Time PCR) 
cDNA synthesis was achieved using 1 μg of total RNA and Reverse Transcriptase (RT; NZYTech, 
Portugal), according to the manufacturer’s instructions. Real-Time PCR was performed in ABI Prism 
7500 Sequence Detection System, using SybrGreen Master Mix (Applied Biosystems® by Life 
Technologies™, USA) and specific primers for the gene of interest (HBB: primer #3 and #4; puromycin 
resistance gene-internal control: primer #5 and #6) (Table 1). Quantification was performed using the 
relative standard curve method (ΔΔCt, Applied Biosystems® by Life Technologies™, USA), following 
the temperature programme on Table 2. Technical triplicates from each experiment, as well as each 
sample, were assessed in all cases. 
3.6. Semiquantitative PCR    
Three dilutions (1:2, 1:4 and 1:8) were prepared using the RT product from the BN sample. 
Three µL of each of the diluted samples were amplified with 0.3 µL of Taq DNA polymerase (5 U/µL; 
Ambion), 5 µL of 10X PCR buffer (with 15 mM MgCl2; Ambion), 0.5 µL of dNTPs (10 mM) and 1 µL of 
each corresponding forward #3 and reverse primer #4 (Table 1) for HBB gene, in a total volume of 50 
µL.  Thermocycler conditions were 95°C for 5 min, followed by 30 cycles of 95°C for 1 min, 60°C for 1 
min, and 72°C for 1 min, followed by a final extension of 72°C for 5 min. The same procedure was 
carried out in parallel using GADPH specific primers (#7 and #8 – Table 1) as the internal control. 
Thermocycler conditions were 95°C for 10 min, followed by 24 cycles of 95°C for 45 sec, 60°C for 30 
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sec, and 72°C for 45 sec, followed by a final extension of 72°C for 10 min. Aliquots from each sample 
were analysed by electrophoresis on 2% agarose gels. 
 
3.7. SDS-PAGE and Western Blot  
Cell lysates were denatured for 10 minutes at 95°C. Twelve µL of SDS sample buffer 5x was 
added to 60 µL of lysate and these were loaded into a 14% polyacrylamide gel and resolved at 
20mA/gel. Then proteins were transferred to a PVDF membrane (Bio-Rad, USA) for 1 hour at 100V. 
The membrane was blocked in 5% (w/v) skimmed milk + TBS-Tween 20 (Sigma-Aldrich®, USA) 0,1% 
(v/v) for 1 hour and probed using mouse anti-α-tubulin antibody (loading control; Roche, 
Switzerland) at 1:10 000 dilution and mouse monoclonal anti-beta globin (Sigma-Aldrich®, USA, USA) 
at 1:250 or rabbit monoclonal anti-c-myc (Santa Cruz Biotechnology Inc., USA) at 1:250 overnight. 
After incubation with the primary antibody, membranes were washed 3 times in TBS-Tween 20 (1X) 
(Sigma-Aldrich®, USA) 0.1% (v/v). Detection was carried out by incubating the membranes for 1 hour 
with the secondary antibodies, peroxidase conjugated anti-mouse IgG (Bio-Rad, USA), anti-rabbit IgG 
(Bio-Rad, USA) antibodies, followed by enhanced chemiluminescence reaction.  
3.8. Statistical analysis 
Results are expressed as mean ± standard deviation of at least 3 experiments in which the 
mRNA levels expressed from B15 and B39-containing plasmids are normalized to the BN mRNA levels 
arbitrarily set to 1. Student’s t test was used for estimation of statistical significance (unpaired, two 
tails). Significance for statistical analysis was defined as p< 0.05. 
 
 
 
 
 
 
 
 
Table 1: Sequences of the primers used in the current work 
Primer Sequence (5’  3’) 
#1 TTGGCATGGAGCAGAAGCTGATCTCCGAGGAGGACCTGGCCCATCACT 
#2 ATGGGCCAGGTCCTCCTCGGAGATCAGCTTCTGCTCCATGCCAAAGTG 
#3 GTGGATCCTGAGAACTTCAGGC 
#4 CAGCACACAGACCAGCACGT 
#5 GGGTCACCGAGCTGCAAGAA 
#6 CACACCTTGCCGATGTCGAG 
#7 CCATGAGAAGTATGACAACAGCC 
#8 GGGTGCTAAGCAGTTGGTG 
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Temperature Time Step 
95°C 10 min. Holding Stage 
95°C 15 sec. 40 cycles 
Cycling Stage 62°C 30 sec. 
95°C 15 sec. 
Melting Curve 
62°C 30 sec. 
95°C 30 sec. 
60°C 15 sec. 
Table 2: Amplification programme used in Real-Time qPCR 
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4. RESULTS 
4.1. Beta globin detection by Western blot 
The first experiment had the purpose of evaluating beta globin protein levels, produced by 
each transcript (BN, B15 and B39). For that, HeLa cells, transiently transfected with the plasmids 
containing the three beta globin variants, were lysed and denatured leaving the protein in solution 
and available to be detected by WB. As observed in Figure 3, it was not possible to detect beta globin 
with the tested conditions. However, we observed α-tubulin with a specific antibody, meaning that 
the WB was correctly carried out. Thus, this negative result may be due to the incapacity of the 
antibody to detect the protein.  
To overcome this obstacle, we decided to clone a c-myc tag in the human HBB gene exon 3, 
specifically in the restriction site of BstXI, using annealing reaction (Figure 4). The two 
oligonucleotides were annealed, following the protocol on Materials and Methods section, forming a 
double stranded oligo (Figure 4a) that was ligated to the plasmid, containing the HBB gene, 
previously digested by BstXI (Appendix Figure 1). With this approach only B39_c-myc variant was 
created (Figure 4b) since for BN and B15 we did not get any transformant colonies, possibly due to 
ligation inefficiency. Because of this problem, a new strategy based on restriction enzymes was 
chosen. For that, NotI and BsrGI enzymes were used to digest the B39_c-myc variant, as well as BN 
and B15, which do not contain the c-myc tag yet. Eventually, the resulting fragments (Appendix 
Figure 2) were ligated. Particularly, the large fragment from the B39_c-myc variant was ligated with 
the small fragments of each BN and B15 variant (Figure 4c). The beta globin gene was fully 
sequenced after the cloning strategy.  
 
 
 
 
 
 
 
 
 
Figure 3: Western blot of cell lysates using an anti-beta globin antibody (Sigma-Aldrich®). The molecular 
weights of the α-tubulin (55 kDa) and beta globin (16 kDa) proteins are indicated on the left side of the 
autoradiography. The first lane corresponds to a sample with non-transfected cells (NT). 
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After obtaining the three variants containing the c-myc tag, we tried to detect beta globin 
protein once again (data not shown), before testing any of the readthrough drugs. The cell culture, 
transfection, cell lysis and WB were performed at the conditions previously used, but this time with 
an anti-c-myc antibody. Unfortunately, it was not possible to detect beta globin once again even 
though the c-myc tag was correctly inserted. This lack of results may be due to a bad transfer of the 
small proteins to the PVDF membrane. To ascertain whether the small proteins are being 
transferred, the membrane was stained with Comassie Blue (Sigma-Aldrich®) which showed that the 
transfer stopped around the 25kDa (Appendix Figure 3a). This problem may be due to the blot buffer 
or the voltage/amperage that were used in the transfer. In order to solve this problem, the blot 
buffer recipe was replaced for the Towbin buffer which is the most suitable for small proteins like 
beta globin (recipe available in Appendix 4). Since there were no noticeable differences in the 
transfer using the Towbin buffer, the original blot buffer was used. It was suggested that blot buffer’s 
recipe might not be correct and, therefore, a blot buffer with a new recipe was made (Appendix 4). 
By using this blot buffer the transfer was much more efficient (Appendix Figure 3b). However, as 
observed in Figure 5, beta globin was not able to be detected, despite all the adjustments to the 
original protocol.  In parallel with the two tested samples (BN and B39) it was decided to run, as a 
Figure 4: Insertion of a c-myc tag in exon 3 of HBB gene. a) Agarose gel of the annealing reaction, from left to 
right: oligonucleotide forward (F), oligonucleotide reverse (R), double stranded oligo (DS), DNA marker – NZY 
DNA ladder VI (M). b) Comparison of the three matching sequences: reference sequence (top), c-myc 
sequence (middle) and B39_c-myc (bottom). c) Cloning strategy to create BN_c-myc and B15_c-myc variants 
using NotI and BsrGI enzymes. 
c-myc tag 
48bp 
B39 
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control, four other samples (C1, C2, C3 and C4) that do not contain beta globin. These four controls 
(gift from Oncobiologia lab, INSA) are lysates which are supposed to contain a small protein - H2B 
histone – with approximately 15 kDa. The purpose of these four samples is to verify if the absence of 
signal in the BN sample is due to a transfer problem during WB. Although α-tubulin is detectable, the 
small proteins could be over transferred, owing to their small molecular weight, passing through the 
PVDF membrane. As we can observe in Figure 5, the small protein used as a control was detected, 
indicating that the absence of beta globin is not due to transfer inefficiency. 
 
 
 
 
 
 
At this point it was suggested that the production of beta globin by the cells was very low due to the 
weak promoter (SV40) present in the pTRE2pur plasmid. To solve this problem, for each beta globin 
variant, two 35-mm plates containing HeLa cells were plated instead of one, concentrating the 
sample at the cell lysis step. The experiment was repeated considering this new alteration and using 
a new control (CP), a lysate in which the protein of interest contains a c-myc tag. The use of this 
control makes it possible to know if the anti-c-myc antibody is working. As we can observe in figure 
6a, the antibody is working since the CP sample shows a clear band, unlike the remaining samples. 
Because there is no simple explanation to the absence of band in the BN sample, as was expected, it 
was decided to test the anti-beta globin one last time (Sigma-Aldrich®) and this time it was possible 
to obtain a band (Figure 6b). Due to the fact that this strategy was not viable owing to time and 
money constrictions, it was decided to continue the work by studying the effect of the G418 and 
PTC124 only at the mRNA level.  
Figure 5: Western blot of cell lysates using anti-c-myc antibody (Santa Cruz biotechnology) and anti-H2B 
antibody (Santa Cruz biotechnology). Only the first two lanes are samples related to the beta globin analysis. 
The other four (C1, C2, C3 and C4) are controls supposed to contain a small protein (H2B histone). (M) 
Molecular weight marker. 
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4.2. Analysis of BN and B39 mRNA levels when transfected HeLa cells are exposed to G418 or 
PTC124  
Our first approach was to evaluate the mRNA levels produced by each transcript before testing 
any of the readthrough drugs. For that, HeLa cells were transfected with a plasmid containing the 
three beta globin gene variants: BN, B15 and B39 and 24 hours post transfection, the cells were lysed 
followed by RNA extraction and cDNA synthesis. The beta globin mRNA levels were quantified by 
Real Time PCR. As it is observed in Figure 7, B39 is 21% and B15 is 83% of the BN, which is arbitrarily 
set to 1, as expected.  
 
 
 
 
 
 
 
 
 
 
Once optimal conditions were verified, it was possible to start the experiments using the 
readthrough compounds. Twenty-four hours after transfection, cell cultures were either treated or 
Figure 6: Western blot of cell lysates using c-myc antibody (Santa Cruz Biotechnology) on (a) and an anti-
beta globin antibody (Sigma-Aldrich®) on (b). These experiments revealed that c-myc and beta globin 
antibodies are working properly, however the first was not able to detect the c-myc tag in our samples. 
Figure 7: RT-qPCR analysis performed on mRNA isolated from HeLa cells expressing the BN, B15 and B39 
transcripts without any drug treatment. Statistical analysis of the three independent experiments compares 
B15 and B39 with the wild-type (BN). p<0,001 
(c-myc Ab) 
r 
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untreated with increasing concentrations (150 µg/ml, 300 µg/ml or 500 µg/ml) of G418 and 
harvested 24 hours later. The RNA was extracted, followed by cDNA synthesis and lastly analysed by 
Real Time PCR (Figure 8). As it is possible to observe in figure 8, G418 did not have a significant 
readthrough effect since there is not a clear increase in the beta globin mRNA levels. The highest 
effect is noticeable in the 500 µg/ml drug concentration, which rose from 12% (B39 0µg/mL) to 21% 
(B39 500µg/mL).  
 
 
 
 
 
 
 
 
 
 
The second drug tested was PTC124 at 6, 9 and 12 µM (Figure 9), using the same experimental 
approach used for G418. Beta globin mRNA levels did not increase in any of the tested 
concentrations excepting at 6 µM that rose slightly from 11% to 16%, when compared to B39 0 µM 
(Figure 9a). In parallel, it was done a semiquantitative PCR to ascertain if it was possible to see any 
clear alterations and, when observing the two lanes that concern the B39 sample, it is noticeable that 
the sample containing the drug is slightly brighter, indicating a higher beta globin expression, 
although the RT-qPCR does not validate that information (Figure 9b). Looking for a more stimulating 
result, we decided to change the drug concentrations. In order to reach that goal, three 
concentrations of PTC124: 3 µM, 30 µM and 100 µM were used, maintaining the remaining 
conditions. This concentration range was chosen based on Welch et al. (2007)40, that uses this drug in 
a different working model.  
Figure 8: RT-qPCR analysis performed on total mRNA isolated from HeLa cells containing the BN and B39 
transcripts after treatment with G418 aminoglycoside - Relative beta globin mRNA levels are normalized to 
the expression of the wild-type mRNA of each condition (BN). Statistical analysis of the three independent 
experiments compares B39 0µg/mL with the B39 of each drug concentration. p>0,05 
NS                   NS                    NS 
r 
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After the RT-qPCR analysis, the results were very promising (Figure 10) since all samples containing 
PTC124 exhibited an increase in the beta globin mRNA levels. The most efficient concentration was 
100 µM, which showed an increase of almost 4-fold (38%) when compared to the B39 0 µM (10%). 
Finally, one last range of concentrations was tested, comprising 50 µM, 100 µM and 150 µM (Figure 
11). 150 µM was the most efficient concentration when the readthrough is concerned, since the beta 
globin mRNA levels duplicated (18%) when compared to the B39 0 µM (9%). 
 
Figure 9: RT-qPCR (a) and semiquantitative PCR (b) performed on RNA isolated from HeLa cells containing 
the BN, B15 and B39 transcripts after treatment with PTC124 – (a) Relative mRNA levels are normalized to 
the expression of the BN mRNA that do not contain drug (first bar). (b) The top bands are referred to the 
GAPDH internal control, being the bottom ones referred to the beta globin. From left to right: DNA marker – 
NZY DNA ladder VI (M); BN 0 µM 1:2; BN 0 µM 1:4; BN 0 µM 1:8; B15 0 µM; B39 0 µM; BN 9 µM; B15 9 µM; 
B39 9 µM; sample that do not contain reverse transcriptase (-RT); positive control (CP); sample that only 
contains the PCR mix (B).  
  
                        DMSO                                           PTC124 
70 kDa 
50 kDa 
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Figure 10: RT-qPCR analysis performed on RNA isolated from HeLa cells expressing the BN and B39 
transcripts after treatment with PTC124 - Relative mRNA levels are normalized to the expression level of the 
BN mRNA of each condition. Statistical analysis of the two independent experiments compares B39 0µM with 
the B39 of each drug concentration. p>0,05 
Figure 11: RT-qPCR analysis performed on RNA isolated from HeLa cells expressing the BN and B39 
transcripts after treatment with PTC124 - Relative beta globin mRNA levels are normalized to the expression 
of the BN mRNA of each condition. Statistical analysis of the three independent experiments compares B39 
0µM with the B39 of each drug concentration. p>0,05 
NS                     NS                     NS 
r 
NS                     NS                     NS 
r 
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5. DISCUSSION AND FUTURE DIRECTION 
The introduction of a PTC in the ORF does not allow the translation to progress until the full-
length protein is synthesized. For this reason, nonsense mutations are the origin of a large 
proportion of all genetic diseases, being imperative the development of a therapy. Suppression 
therapy utilizes low molecular weight compounds that induce the translation machinery to recode a 
PTC into a sense codon, allowing the translation elongation to continue in the correct reading frame 
until it reaches a normal stop codon, culminating with the formation of a full-length polypeptide31. 
Although the translation termination process is generally accurate, the readthrough process can 
naturally occur if a near-cognate aminoacyl-tRNA (whose anticodon is complementary to two of the 
three nucleotides of the codon) binds the stop codon32. The error rate for suppression of normal stop 
codons at the end of genes is generally less than at premature termination codons. Suppression 
generally occurs at a rate of 0.001–0.1% at normal stop codons42 and 0.01–1% at PTCs35.  
In the present thesis the aim was to ascertain how beta thalassemic nonsense mutation at 
codon 39 will respond to nonsense suppression therapy with an aminoglycoside, G418, or a non-
aminoglycoside, PTC124. The final purpose is to discover which compounds will have efficient levels 
of suppression, in a dose-dependent manner.  
The intention was to analyze the effect of these two compounds in the mRNA as well as in 
protein levels to obtain more complete and accurate information about the readthrough ability of 
each drug. Concerning the mRNA analysis (Figure 7), the results were in line with literature. B39 
transcript exhibited a level of expression of 21% when compared to the wild type, indicating that 
these nonsense-mutated mRNAs undergo rapid decay, as demonstrated by Romão et al., 200043. 
Statistical analysis indicated that there is a significant difference between the mRNA levels of BN and 
B39 (p<0,001). The low levels of the B39 transcript is explained by the fact that it possesses a PTC 
localized at more than 50-55 nts upstream of the last exon-exon junction and so the ribosome is 
incapable to physically remove downstream EJCs, activating NMD16. On the other hand, B15 levels 
are identical to the wild type transcript as it was expected. Although this transcript has a nonsense 
mutation on codon 15 and, for this reason, has downstream EJCs, it fails to trigger NMD, due to the 
fact that it is in close proximity to the translation initiation codon (AUG-proximal PTC)17. The 
mechanism for this NMD resistance was related to the fact that the PABPC1 is capable of inhibiting 
NMD when placed close to a PTC, even in the presence of EJCs44. Taking this into account and that 
the mRNA acquires a circular conformation owing to the interactions of PABPC1 with the scaffold 
protein eIF4G at the 5’-Cap, eIF3 (eukaryotic initiation factor 3) and the 40S ribosome, it is supposed 
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that the PABPC1 is relocated into the AUG vicinity during 40S ribosome scanning. In these conditions, 
the PABPC1 might be placed near AUG proximal EJCs and might be able to prevent NMD activation.  
When protein analysis is concerned, obtaining the band correspondent to the beta globin was 
not an easy task (Figures 3 and 5). Beta globin is a small protein (16kDa) and, for that reason, the 
transfer conditions require special attention. Besides, due to the weak promoter of the pTRE2pur 
plasmid, the production of beta globin was not sufficient to be detected by WB. After many 
adjustments in the protocol, namely on the cell lysis, beta globin was detected (Figure 6), but since it 
was not a viable procedure, it was decided to continue the study only by focusing on the mRNA 
levels. The ideal at this point would be to clone the HBB gene on a plasmid with a strong promoter to 
avoid the concentration step, which spends a lot of time and money.  The cloning strategy is already 
planned and starting to be performed using pcDNA3 plasmid and cloning the FLAG tag before the 
3’UTR. 
Once the basal conditions concerning the beta globin mRNA levels were verified, the 
readthrough tests using G418 started.  G418 did not have a significant readthrough effect because 
there is not a clear increase in the beta globin mRNA levels (Figure 8). The biggest effect is noticeable 
in the highest drug concentration, which achieved 21% of the wild type where the same transcript 
without drug only reaches 12%. The observed increase may be due to the capacity of the 
aminoglycoside to bind to the decoding centre of the ribosome, leading to the reduction of 
translation fidelity by reducing the proofreading ability of the ribosome and increasing the 
misincorporation of near-cognate aminoacyl tRNAs into the ribosomal A site at stop codons, resulting 
in translational misreading at PTCs5. 
The second drug chosen to be tested as a readthrough compound was PTC124 (Ataluren), a 
non-aminoglycoside much less studied than G418 but very promising owing to its efficiency and 
nontoxic characteristics. After an extensive research in literature, the concentrations proposed to be 
tested were 6, 9 and 12 µM mainly suggested by Lentini et al., 201445. The experimental approach 
was equal to the previously used for G418, being the results not as good as it was expected (Figure 
9). The concentrations were altered after an extensive research in papers related to our work. One of 
the articles was Welch et al. (2007)40, which tested three concentrations of PTC124: 3 µM, 30 µM and 
100 µM and obtained great readthrough results. Although the study model was very different from 
the one used in this thesis, it was decided to use those three concentrations but to maintain the 
remaining conditions. The results obtained when using these new conditions were very encouraging 
(Figure 10). In fact, the rise of the beta globin mRNA levels was proportional to the concentration of 
PTC124 supporting the results shown by Welch et al40. B39 transcript at the highest concentration 
(100 µM) showed an increase of nearly 4-fold when comparing with the B39 without drug. It is 
24 
 
known that PTC124 presents a bell-shaped dose-response curve, which results in a therapeutic 
response only within a narrow dose range46 and so it was decided to test one last range of 
concentrations in order to see if this bell-shaped dose-response curve was visible in this study model. 
For that, the concentrations tested were 50 µM, 100 µM and 150 µM (Figure 11). Regarding this 
experiment, the results were not as favorable as they were in the previous testing because the 
difference between the control and the other samples was not so pronounced. In parallel, the 150 
µM was the most efficient concentration resulting in a 2-fold increase. It was not possible to 
conclude if PTC124 exhibits a bell-shaped dose-response curve since the mRNA levels continued to 
increase until the highest concentration tested. 
The response to this type of treatment is variable. A possible explanation for the variability in 
the results is the different PTCs involved and the context surrounding them (specially the fourth 
nucleotide). The UGA codon followed by a C has been reported to be the best combination for 
readthrough or efficiency as a STOP codon. Besides the nucleotide in the 4th position, the first 
nucleotide 5’ of the PTC is also important, with U being more susceptible to promote 
readthrough47,48. 
When comparing the two tested drugs, it is possible to observe that PTC124 presented better 
results than G418 since the best increase concerning PTC124 was 28% and for G418 was 9%. To 
obtain more conclusions about these two readthrough compounds, it is necessary to test other 
concentration ranges. Moreover, it is interesting to test this approach in another cell model, namely 
in erythroid cells like murine erythroleukemia (MEL) cells, because it is a much more realistic model. 
In fact, our laboratorial group usually works with this cell line so, in parallel, some strategies were 
established for the future experiments.  
As a conclusion, although readthrough therapy is a very difficult and challenging field of 
investigation, it is very promising as well, since it offers a possible cure not just for one disease but 
for a big number of patients that suffer from genetic diseases caused by nonsense mutations, such as 
beta thalassemia. 
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Appendix figure 1: 0,8% agarose gel electrophoresis showing the digestion of the pTRE2pur plasmid, 
containing the beta globin gene, by BstXI restriction enzyme. From left to right DNA marker – NZY 
DNA ladder III (M), non-digested (ND), pTRE2pur_BN (BN), pTRE2pur_B15 (B15), pTRE2pur_B39 
(B39). 
5540bp 
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Appendix figure 2: 2% agarose gel electrophoresis showing the digestion of the pTRE2pur plasmid, 
containing the beta globin gene, by NotI and BsrGI restriction enzymes. From left to right DNA 
marker – NZY DNA ladder III (M), pTRE2pur_BN (BN), pTRE2pur_B15 (B15), pTRE2pur_B39_c-myc 
(B39). 
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Appendix figure 3: Western blot transfer using two different blot buffers. a) The original blot buffer. 
b) Fresh blot buffer using a new recipe.  
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APPENDIX 4 
 Original Blot Buffer (25X) Towbin Buffer (25X) New Blot Buffer (25X) 
Tris 145g 75,8g 145g 
Glycine 72,5g 360,3g 72,5g 
Methanol 20% 20% 20% 
SDS 1,25g ------ 9,3g 
H20 ↑H2O ↑H2O  ↑H2O 
Appendix figure 4: Recipes of the three Western blot buffers used in this work. 
